DK1689726T3 - 5-(benz-(z)-yliden)-thiazolidin-4-on-derivater som immunsuppresserende midler - Google Patents
5-(benz-(z)-yliden)-thiazolidin-4-on-derivater som immunsuppresserende midlerInfo
- Publication number
- DK1689726T3 DK1689726T3 DK04819591.1T DK04819591T DK1689726T3 DK 1689726 T3 DK1689726 T3 DK 1689726T3 DK 04819591 T DK04819591 T DK 04819591T DK 1689726 T3 DK1689726 T3 DK 1689726T3
- Authority
- DK
- Denmark
- Prior art keywords
- thiazolidin
- immunosuppressants
- benz
- ylidene
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP0313072 | 2003-11-21 | ||
PCT/EP2004/012953 WO2005054215A1 (en) | 2003-11-21 | 2004-11-16 | 5-(benz- (z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1689726T3 true DK1689726T3 (da) | 2010-12-06 |
Family
ID=34639216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04819591.1T DK1689726T3 (da) | 2003-11-21 | 2004-11-16 | 5-(benz-(z)-yliden)-thiazolidin-4-on-derivater som immunsuppresserende midler |
Country Status (26)
Country | Link |
---|---|
US (8) | US7435828B2 (da) |
EP (2) | EP1689726B1 (da) |
JP (2) | JP4061332B2 (da) |
KR (1) | KR100783835B1 (da) |
CN (1) | CN100567275C (da) |
AR (1) | AR047128A1 (da) |
AT (1) | ATE483698T1 (da) |
AU (1) | AU2004295047B2 (da) |
BR (1) | BRPI0416752B8 (da) |
CA (1) | CA2545582C (da) |
CY (1) | CY1111087T1 (da) |
DE (1) | DE602004029493D1 (da) |
DK (1) | DK1689726T3 (da) |
ES (1) | ES2352555T3 (da) |
HR (1) | HRP20100714T1 (da) |
IL (1) | IL175758A (da) |
MY (1) | MY145074A (da) |
NO (1) | NO336734B1 (da) |
NZ (1) | NZ547962A (da) |
PL (1) | PL1689726T3 (da) |
PT (1) | PT1689726E (da) |
RU (1) | RU2379299C2 (da) |
SI (1) | SI1689726T1 (da) |
TW (1) | TWI323659B (da) |
WO (1) | WO2005054215A1 (da) |
ZA (1) | ZA200605077B (da) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004029493D1 (de) * | 2003-11-21 | 2010-11-18 | Actelion Pharmaceuticals Ltd | 5-(benz- (z) -yliden) -thiazolidin-4-onderivate als das immunsystem unterdrückende mittel |
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
JP2007523957A (ja) * | 2004-02-25 | 2007-08-23 | スミスクライン・ビーチャム・コーポレイション | 新規化学化合物 |
WO2006020951A1 (en) | 2004-08-13 | 2006-02-23 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity |
EP2298308B1 (en) * | 2005-11-14 | 2013-01-16 | University Of Southern California | Integrin-binding small molecules |
JP4182986B2 (ja) * | 2006-04-19 | 2008-11-19 | トヨタ自動車株式会社 | 半導体装置とその製造方法 |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
DK2094676T3 (da) | 2006-11-23 | 2013-06-10 | Actelion Pharmaceuticals Ltd | Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater |
WO2009115954A1 (en) * | 2008-03-17 | 2009-09-24 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
GB0819182D0 (en) * | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
WO2012015758A2 (en) * | 2010-07-30 | 2012-02-02 | Saint Louis University | Methods of treating pain |
PT2885266T (pt) | 2012-08-17 | 2020-05-29 | Actelion Pharmaceuticals Ltd | Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo |
EP2990055B1 (en) | 2013-04-26 | 2019-06-05 | Kyoto University | Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it |
EP2862574A1 (en) | 2013-10-15 | 2015-04-22 | Sanofi | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
EP2952188A1 (en) * | 2014-06-03 | 2015-12-09 | Universität Bern | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation |
WO2015181336A1 (en) * | 2014-05-28 | 2015-12-03 | Universität Bern | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation |
AU2015265865B2 (en) * | 2014-05-28 | 2020-05-07 | Universitat Bern | Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
AU2015359346B2 (en) | 2014-12-11 | 2020-05-07 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective S1P1 receptor agonist |
US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
US10487064B1 (en) | 2015-12-25 | 2019-11-26 | Crystal Pharmatech Co., Ltd. | Crystalline forms of selective S1P1 receptor modulator and preparation method thereof |
JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
WO2019060147A1 (en) * | 2017-09-19 | 2019-03-28 | Teva Pharmaceuticals Usa, Inc. | NEW CRYSTALLINE POLYMORPHE FROM PONESIMOD |
TWI647229B (zh) * | 2017-11-14 | 2019-01-11 | 國立暨南國際大學 | Method for synthesizing 3,4-hydroisoquinoline thiazolidine |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
CA3156298A1 (en) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
US20230055568A1 (en) | 2020-02-06 | 2023-02-23 | Mitsubishi Tanabe Pharma Corporation | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome |
WO2023022896A1 (en) | 2021-08-17 | 2023-02-23 | Teva Czech Industries S.R.O | Polymorphs of ponesimod |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
WO2023152691A1 (en) * | 2022-02-10 | 2023-08-17 | Metrochem Api Pvt Ltd | Process for the preparation of ponesimod and its intermediates thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3077402A (en) | 1954-12-06 | 1963-02-12 | Polaroid Corp | Photographic color processes, products, and compositions |
NL270002A (da) | 1960-10-08 | |||
OA03835A (fr) | 1970-07-17 | 1971-12-24 | Rhone Poulenc Sa | Nouveaux dérivés de la thiazolidine, leur préparation et les compositions qui les contiennent. |
HU214872B (hu) | 1990-04-27 | 1998-07-28 | Orion-Yhtymä Oy | Eljárás farmakológiailag aktív új katecholszármazékok és ezeket tartalmazó gyógyászati készítmények előállítására |
TW221689B (da) | 1991-08-27 | 1994-03-11 | Otsuka Pharma Co Ltd | |
CA2134347C (en) | 1993-02-26 | 2003-04-29 | Koichi Yasumura | Thiazole or imidazole derivatives as maillard reaction inhibitors |
KR960022486A (ko) * | 1994-12-29 | 1996-07-18 | 김준웅 | 신규 티아졸리딘-4-온 유도체 |
US6353006B1 (en) | 1999-01-14 | 2002-03-05 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
AU6877300A (en) * | 1999-09-14 | 2001-04-17 | Shionogi & Co., Ltd. | 2-imino-1,3-thiazine derivatives |
DE69934027T2 (de) | 1999-11-12 | 2007-06-21 | Fujimoto Brothers Co., Ltd., Matubara | 2-(n-cyanimino)thiazolidin-4-on derivate |
US20050019825A9 (en) * | 2002-03-15 | 2005-01-27 | Qing Dong | Common ligand mimics: pseudothiohydantoins |
AU2003255528B2 (en) | 2002-07-10 | 2009-07-16 | Merck Serono Sa | Azolidinone-vinyl fused-benzene derivatives |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
WO2004014313A2 (en) | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Combination pharmaceutical agents as inhibitors of hcv replication |
KR20050085115A (ko) | 2002-11-22 | 2005-08-29 | 스미스클라인 비참 코포레이션 | 신규 화합물 |
US20040167192A1 (en) | 2003-01-16 | 2004-08-26 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
DE602004029493D1 (de) | 2003-11-21 | 2010-11-18 | Actelion Pharmaceuticals Ltd | 5-(benz- (z) -yliden) -thiazolidin-4-onderivate als das immunsystem unterdrückende mittel |
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
JP2007523957A (ja) | 2004-02-25 | 2007-08-23 | スミスクライン・ビーチャム・コーポレイション | 新規化学化合物 |
WO2006094233A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N,n'-dicyclic isothiourea sirtuin modulators |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
DK2094676T3 (da) | 2006-11-23 | 2013-06-10 | Actelion Pharmaceuticals Ltd | Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater |
WO2009115954A1 (en) | 2008-03-17 | 2009-09-24 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
-
2004
- 2004-11-16 DE DE602004029493T patent/DE602004029493D1/de active Active
- 2004-11-16 EP EP04819591A patent/EP1689726B1/en active Active
- 2004-11-16 PL PL04819591T patent/PL1689726T3/pl unknown
- 2004-11-16 SI SI200431556T patent/SI1689726T1/sl unknown
- 2004-11-16 JP JP2006540283A patent/JP4061332B2/ja active Active
- 2004-11-16 AU AU2004295047A patent/AU2004295047B2/en active Active
- 2004-11-16 PT PT04819591T patent/PT1689726E/pt unknown
- 2004-11-16 EP EP10007267A patent/EP2295418A1/en not_active Withdrawn
- 2004-11-16 US US10/580,169 patent/US7435828B2/en not_active Ceased
- 2004-11-16 AT AT04819591T patent/ATE483698T1/de active
- 2004-11-16 WO PCT/EP2004/012953 patent/WO2005054215A1/en active Application Filing
- 2004-11-16 NZ NZ547962A patent/NZ547962A/en unknown
- 2004-11-16 US US13/194,172 patent/USRE43728E1/en active Active
- 2004-11-16 CN CNB2004800342094A patent/CN100567275C/zh active Active
- 2004-11-16 CA CA2545582A patent/CA2545582C/en active Active
- 2004-11-16 KR KR1020067009783A patent/KR100783835B1/ko active IP Right Grant
- 2004-11-16 ES ES04819591T patent/ES2352555T3/es active Active
- 2004-11-16 BR BRPI0416752A patent/BRPI0416752B8/pt active IP Right Grant
- 2004-11-16 DK DK04819591.1T patent/DK1689726T3/da active
- 2004-11-16 RU RU2006121651/04A patent/RU2379299C2/ru active
- 2004-11-19 MY MYPI20044811A patent/MY145074A/en unknown
- 2004-11-19 TW TW093135720A patent/TWI323659B/zh active
- 2004-11-19 AR ARP040104281A patent/AR047128A1/es active IP Right Grant
-
2006
- 2006-05-18 IL IL175758A patent/IL175758A/en active IP Right Grant
- 2006-05-30 NO NO20062483A patent/NO336734B1/no unknown
- 2006-06-20 ZA ZA200605077A patent/ZA200605077B/en unknown
-
2007
- 2007-10-26 JP JP2007279142A patent/JP4129286B2/ja active Active
-
2008
- 2008-02-05 US US12/026,277 patent/US7626037B2/en not_active Ceased
- 2008-06-03 US US12/132,443 patent/US7875726B2/en not_active Ceased
-
2009
- 2009-07-02 US US12/496,945 patent/US8273779B2/en active Active
-
2010
- 2010-12-10 CY CY20101101140T patent/CY1111087T1/el unknown
- 2010-12-21 HR HR20100714T patent/HRP20100714T1/hr unknown
-
2012
- 2012-08-09 US US13/570,956 patent/US8524752B2/en active Active
-
2013
- 2013-07-26 US US13/951,954 patent/US9000018B2/en active Active
- 2013-09-17 US US14/028,712 patent/USRE45174E1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1689726T3 (da) | 5-(benz-(z)-yliden)-thiazolidin-4-on-derivater som immunsuppresserende midler | |
CY2015036I2 (el) | Νεα παραγωγα οξαζολιδινονης | |
NO20053215D0 (no) | Pyrazolderivater med anvendelse som COX-1-inhibitorer. | |
NO20053775D0 (no) | Diazepinoindol derivater som kinaseinhibitorer. | |
DK1789041T3 (da) | Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer | |
ATE340782T1 (de) | Piperidinbenzolsulfonamidderivate | |
DK1797042T3 (da) | Indozolonderivater som 11B-HSD1-inhibitorer | |
DK1682493T3 (da) | Amidoacetonitrilderivater | |
MA28554B1 (fr) | Dérivés de morpholine | |
IS2656B (is) | Nýjar besímídasólafleiður | |
NO20050665L (no) | Pyrrolidonderivater som MAOE inhibitoere | |
DK1492785T3 (da) | 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer | |
DK1663232T3 (da) | Benzimidazolderivater som human chymase-inhibitorer | |
IS8578A (is) | 3- karbamoýl - 2- pýridón afleiður | |
DK1828167T3 (da) | Acrylamidderivater som antibiotiske midler | |
ATE478870T1 (de) | Spiroindolinpiperidinderivate | |
ATE460418T1 (de) | Heterocyclocarboxamidderivate | |
ATE467631T1 (de) | Chinuclidinamidderivate | |
DK1761541T3 (da) | Pyrrazolo-pyrimidin-derivater | |
DK1474408T3 (da) | N-Phenyl-2-pyrimidinaminderivater | |
ATE540935T1 (de) | Chinazolinderivate | |
DK1638928T3 (da) | N-alkynyl-2-(substituerede aryloxy)alkylthio-amidderivater som fungicider | |
ATE417830T1 (de) | Sulfonylbenzimidazolderivate | |
DK1740569T3 (da) | Imidazol-derivater som TAFla-inhibitorer | |
IS8364A (is) | N-þíasól-2-ýl-bensamíð afleiður |